Supporting Information

Wei *et al.* 10.1073/pnas.0810676105



Fig. S1. Knockdown of Srx impairs AP-1 activation. (*A*) Serum and EGF induce Srx expression in control cells but not in ShSrx cells. P+ cells stably expressing ShNT or ShSrx were serum-starved for 24 h and then treated as indicated for 6 h. Cell lysates were used for Western blotting. (*B*) Cells after serum starvation were treated with 10-ng/ml TPA for indicated time and Western blotting was performed.



Fig. S2. Srx is not required for NFκB activation. (*A*) A representative luciferase reporter assay in cells stably expressing ShNT or ShSrx by transient transfection of NFκB luciferase reporter construct with a renila luciferase construct. The RLU was determined as the ratio of firefly luciferase value versus renila luciferase value. The assays were performed in triplicates. Data are presented as $\bar{x} \pm$ SD. *, $P > 0.05$ (*t* test). (*B*) Luciferase reporter assay as in (*A*), but using wild-type P+ cells, with or without co-expression of Srx. *, $P > 0.05$ (*t* test).



Fig. S3. Knockdown of Srx increases cell death under oxidative stress conditions. (*A* and *B*) Cells stably expressing vector, ShNT or ShSrx were growing until confluence and then treated with H_2O_2 for 24 h. Cell survival was measured by XTT assay. Data at each concentration are from six replicates and are presented as $\bar{x} \pm$ SD.



Fig. S4. Representative immunohistochemistry staining of Srx in other human tumors. Strong positive staining is found in adenocarcinoma from rectum (*B*) and lung (*D*), but not in normal adjacent rectum (*A*) and lung (*C*) tissues.

Table S1. A summary of Srx immunohistochemistry staining in human skin diseases on tissue microarray.

		Srx immunohistochemistry stain grading				
			Positive			
Number tissue	Total	Negative	+ (%)	+ + (%)	+ + + (%)	Positive/Total (%)
Chronic inflammation	39	36	3 (7.7)	0	0	3/39 (7.7)
Hyperplasia	12	12	0	0	0	0/12
Dermatofibro- sarcoma	9	9	0	0	0	0/9
Condyloma	20	20	0	0	0	0/20
Papilloma	6	4	2	0	0	2/6
Squamous cell carcinoma	59	7	36 (61)	16 (27)	0	52/59 (88.1)
Sweat gland carcinoma	11	2	5 (45.5)	3 (27.3)	1 (9.1)	9/11 (81.8)
Basal cell carcinoma	43	11	16 (37.2)	4 (9.3)	12 (27.9)	32/43 (74.4)
Melanoma	46	16	8 (17.4)	6 (13)	16 (34.8)	30/46 (65.2)